Protecting white matter from stroke injury

Stroke

Volumn 44, Issue 4, 2013, Pages 1204-1211

  Matute, Carlos ^a   Domercq, María ^a   Pérez Samartín, Alberto ^a   Ransom, Bruce R ^b  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 6 CYANO 7 NITRO 2,3 QUINOXALINEDIONE; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; 7 CHLOROKYNURENIC ACID; ADENOSINE; ATIPAMEZOLE; BENZAMIL; BEPRIDIL; BRIMONIDINE; CITICOLINE; DICHLOROBENZAMIL; DIHYDROKAINIC ACID; DIZOCILPINE; EBSELEN; GLUCOSE; GLUCOSE TRANSPORTER; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 2; GLUCOSE TRANSPORTER 3; LACTIC ACID; MECAMYLAMINE; MEDETOMIDINE; MEFLOQUINE; MEMANTINE; MINOCYCLINE; NORPHENAZONE; PROPOFOL; SAXITOXIN; TETRODOTOXIN; UNINDEXED DRUG;

ASTROCYTE; BRAIN ISCHEMIA; BRAIN METABOLISM; CENTRAL NERVOUS SYSTEM; CEREBROVASCULAR ACCIDENT; CORPUS CALLOSUM; ENDOTHELIUM CELL; GLIA CELL; GRAY MATTER; HUMAN; MICROGLIA; MYELINATION; NERVE FIBER; NEUROPATHOLOGY; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; OLIGODENDROGLIA; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; SYNAPSE; SYNAPTIC TRANSMISSION; TREATMENT INDICATION; WHITE MATTER; WHITE MATTER INJURY;

ADENOSINE TRIPHOSPHATE; ANIMALS; AXONS; BRAIN; BRAIN INJURIES; CALCIUM; DISEASE MODELS, ANIMAL; HUMANS; ISCHEMIA; MODELS, BIOLOGICAL; NERVE FIBERS, MYELINATED; NEUROTRANSMITTER AGENTS; SIGNAL TRANSDUCTION; STROKE;

EID: 84876293002     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.112.658328     Document Type: Review

References (81)

1. Zhang K, Sejnowski TJ. A universal scaling law between gray matter and white matter of cerebral cortex. Proc Natl Acad Sci USA. 2000;97:5621-5626.
2. Hamner MA, Möller T, Ransom BR. Anaerobic function of CNS white matter declines with age. J Cereb Blood Flow Metab. 2011;31:996-1002.
3. Ransom BR, Baltan SB. Axons get excited to death. Ann Neurol. 2009;65:120-121.
4. Fisher CM. Lacunes: small, deep cerebral infarcts. Neurology. 2011;77:2104.
5. Patel B, Markus HS. Magnetic resonance imaging in cerebral small vessel disease and its use as a surrogate disease marker. Int J Stroke. 2011;6:47-59.
6. Goldberg MP, Ransom BR. New light on white matter. Stroke. 2003;34:330-332.
7. Pantoni L, Garcia JH, Gutierrez JA. Cerebral white matter is highly vulnerable to ischemia. Stroke. 1996;27:1641-1646; discussion 1647.
8. Shereen A, Nemkul N, Yang D, Adhami F, Dunn RS, Hazen ML, et al. Ex vivo diffusion tensor imaging and neuropathological correlation in a murine model of hypoxia-ischemia-induced thrombotic stroke. J Cereb Blood Flow Metab. 2011;31:1155-1169.
9. Stys PK, Waxman SG, Ransom BR. Ionic mechanisms of anoxic injury in mammalian CNS white matter: role of Na+ channels and Na(+)-Ca2+ exchanger. J Neurosci. 1992;12:430-439.
10. Fern R, Waxman SG, Ransom BR. Modulation of anoxic injury in CNS white matter by adenosine and interaction between adenosine and GABA. J Neurophysiol. 1994;72:2609-2616.
11. Baltan S, Besancon EF, Mbow B, Ye Z, Hamner MA, Ransom BR. White matter vulnerability to ischemic injury increases with age because of enhanced excitotoxicity. J Neurosci. 2008;28:1479-1489.
12. Li S, Mealing GA, Morley P, Stys PK. Novel injury mechanism in anoxia and trauma of spinal cord white matter: glutamate release via reverse Na+-dependent glutamate transport. J Neurosci. 1999;19:RC16.
13. Alix JJ, Fern R. Glutamate receptor-mediated ischemic injury of premyelinated central axons. Ann Neurol. 2009;66:682-693.
14. Nikolaeva MA, Richard S, Mouihate A, Stys PK. Effects of the noradrenergic system in rat white matter exposed to oxygen-glucose deprivation in vitro. J Neurosci. 2009;29:1796-1804.
15. Domercq M, Perez-Samartin A, Aparicio D, Alberdi E, Pampliega O, Matute C. P2X7 receptors mediate ischemic damage to oligodendrocytes. Glia. 2010;58:730-740.
16. Fern R, Möller T. Rapid ischemic cell death in immature oligodendrocytes: a fatal glutamate release feedback loop. J Neurosci. 2000;20:34-42.
17. Salter MG, Fern R. NMDA receptors are expressed in developing oligodendrocyte processes and mediate injury. Nature. 2005;438:1167-1171.
18. Micu I, Jiang Q, Coderre E, Ridsdale A, Zhang L, Woulfe J, et al. NMDA receptors mediate calcium accumulation in myelin during chemical ischaemia. Nature. 2006;439:988-992.
19. Káradóttir R, Cavelier P, Bergersen LH, Attwell D. NMDA receptors are expressed in oligodendrocytes and activated in ischaemia. Nature. 2005;438:1162-1166.
20. Manning SM, Talos DM, Zhou C, Selip DB, Park HK, Park CJ, et al. NMDA receptor blockade with memantine attenuates white matter injury in a rat model of periventricular leukomalacia. J Neurosci. 2008;28:6670-6678.
21. Wang LY, Cai WQ, Chen PH, Deng QY, Zhao CM. Downregulation of P2X7 receptor expression in rat oligodendrocyte precursor cells after hypoxia ischemia. Glia. 2009;57:307-319.
22. Melani A, Cipriani S, Vannucchi MG, Nosi D, Donati C, Bruni P, et al. Selective adenosine A2a receptor antagonism reduces JNK activation in oligodendrocytes after cerebral ischaemia. Brain. 2009;132(pt 6):1480-1495.
23. Carty ML, Wixey JA, Colditz PB, Buller KM. Post-insult minocycline treatment attenuates hypoxia-ischemia-induced neuroinflammation and white matter injury in the neonatal rat: a comparison of two different dose regimens. Int J Dev Neurosci. 2008;26:477-485.
24. Constantinou S, Fern R. Conduction block and glial injury induced in developing central white matter by glycine, GABA, noradrenalin, or nicotine, studied in isolated neonatal rat optic nerve. Glia. 2009;57:1168-1177.
25. Shen Y, Liu XB, Pleasure DE, Deng W. Axon-glia synapses are highly vulnerable to white matter injury in the developing brain. J Neurosci Res. 2012;90:105-121.
26. Turner CP, Seli M, Ment L, Stewart W, Yan H, Johansson B, et al. A1 adenosine receptors mediate hypoxia-induced ventriculomegaly. Proc Natl Acad Sci USA. 2003;100:11718-11722.
27. Imai H, Masayasu H, Dewar D, Graham DI, Macrae IM. Ebselen protects both gray and white matter in a rodent model of focal cerebral ischemia. Stroke. 2001;32:2149-2154.
28. Lee HJ, Kang JS, Kim YI. Citicoline protects against cognitive impairment in a rat model of chronic cerebral hypoperfusion. J Clin Neurol. 2009;5:33-38.
29. Diederich K, Frauenknecht K, Minnerup J, Schneider BK, Schmidt A, Altach E, et al. Citicoline enhances neuroregenerative processes after experimental stroke in rats. Stroke. 2012;43:1931-1940.
30. Ohtani R, Tomimoto H, Wakita H, Kitaguchi H, Nakaji K, Takahashi R. Expression of S100 protein and protective effect of arundic acid on the rat brain in chronic cerebral hypoperfusion. Brain Res. 2007;1135:195-200.
31. Wender R, Brown AM, Fern R, Swanson RA, Farrell K, Ransom BR. Astrocytic glycogen influences axon function and survival during glucose deprivation in central white matter. J Neurosci. 2000;20:6804-6810.
32. Arluison M, Quignon M, Thorens B, Leloup C, Penicaud L. Immunocytochemical localization of the glucose transporter 2 (GLUT2) in the adult rat brain. II. Electron microscopic study. J Chem Neuroanat. 2004;28:137-146.
33. Yu S, Ding WG. The 45 kDa form of glucose transporter 1 (GLUT1) is localized in oligodendrocyte and astrocyte but not in microglia in the rat brain. Brain Res. 1998;797:65-72.
34. Harris JJ, Attwell D. The energetics of CNS white matter. J Neurosci. 2012;32:356-371.
35. Brown AM, Ransom BR. Astrocyte glycogen and brain energy metabolism. Glia. 2007;55:1263-1271.
36. Fünfschilling U, Supplie LM, Mahad D, Boretius S, Saab AS, Edgar J, et al. Glycolytic oligodendrocytes maintain myelin and long-Term axonal integrity. Nature. 2012;485:517-521.
37. Brown AM, Baltan Tekkök S, Ransom BR. Energy transfer from astrocytes to axons: the role of CNS glycogen. Neurochem Int. 2004;45:529-536.
38. Bélanger M, Allaman I, Magistretti PJ. Brain energy metabolism: focus on astrocyte-neuron metabolic cooperation. Cell Metab. 2011;14:724-738.
39. Tsutsui S, Stys PK. Degeneration versus autoimmunity in multiple sclerosis. Ann Neurol. 2009;66:711-713.
40. Brown AM, Tekkök SB, Ransom BR. Glycogen regulation and functional role in mouse white matter. J Physiol (Lond). 2003;549(pt 2):501-512.
41. Rinholm JE, Hamilton NB, Kessaris N, Richardson WD, Bergersen LH, Attwell D. Regulation of oligodendrocyte development and myelination by glucose and lactate. J Neurosci. 2011;31:538-548.
42. Attwell D, Buchan AM, Charpak S, Lauritzen M, Macvicar BA, Newman EA. Glial and neuronal control of brain blood flow. Nature. 2010;468:232-243.
43. Sánchez-Abarca LI, Tabernero A, Medina JM. Oligodendrocytes use lactate as a source of energy and as a precursor of lipids. Glia. 2001;36:321-329.
44. Nave KA. Myelination and support of axonal integrity by glia. Nature. 2010;468:244-252.
45. Rouach N, Koulakoff A, Abudara V, Willecke K, Giaume C. Astroglial metabolic networks sustain hippocampal synaptic transmission. Science. 2008;322:1551-1555.
46. Sozmen EG, Hinman JD, Carmichael ST. Models that matter: white matter stroke models. Neurotherapeutics. 2012;9:349-358.
47. Waxman SG, Black JA, Stys PK, Ransom BR. Ultrastructural concomitants of anoxic injury and early post-Anoxic recovery in rat optic nerve. Brain Res. 1992;574:105-119.
48. Bernstein SL, Guo Y, Kelman SE, Flower RW, Johnson MA. Functional and cellular responses in a novel rodent model of anterior ischemic optic neuropathy. Invest Ophthalmol Vis Sci. 2003;44:4153-4162.
49. Hughes PM, Anthony DC, Ruddin M, Botham MS, Rankine EL, Sablone M, et al. Focal lesions in the rat central nervous system induced by endothelin-1. J Neuropathol Exp Neurol. 2003;62:1276-1286.
50. Shibata M, Ohtani R, Ihara M, Tomimoto H. White matter lesions and glial activation in a novel mouse model of chronic cerebral hypoperfusion. Stroke. 2004;35:2598-2603.
51. Jalal FY, Yang Y, Thompson J, Lopez AC, Rosenberg GA. Myelin loss associated with neuroinflammation in hypertensive rats. Stroke. 2012;43:1115-1122.
52. Matute C, Ransom BR. Roles of white matter in central nervous system pathophysiologies. ASN Neuro. 2012;e00079.
53. Attwell D, Laughlin SB. An energy budget for signaling in the grey matter of the brain. J Cereb Blood Flow Metab. 2001;21:1133-1145.
54. Howarth C, Peppiatt-Wildman CM, Attwell D. The energy use associated with neural computation in the cerebellum. J Cereb Blood Flow Metab. 2010;30:403-414.
55. Bakiri Y, Burzomato V, Frugier G, Hamilton NB, Káradóttir R, Attwell D. Glutamatergic signaling in the brain's white matter. Neuroscience. 2009;158:266-274.
56. Matute C. Glutamate and ATP signalling in white matter pathology. J Anat. 2011;219:53-64.
57. Wake H, Lee PR, Fields RD. Control of local protein synthesis and initial events in myelination by action potentials. Science. 2011;333:1647-1651.
58. Ouardouz M, Coderre E, Basak A, Chen A, Zamponi GW, Hameed S, et al. Glutamate receptors on myelinated spinal cord axons: I. GluR6 kainate receptors. Ann Neurol. 2009;65:151-159.
59. Ouardouz M, Coderre E, Zamponi GW, Hameed S, Yin X, Trapp BD, et al. Glutamate receptors on myelinated spinal cord axons: II. AMPA and GluR5 receptors. Ann Neurol. 2009;65:160-166.
60. Sasaki T, Matsuki N, Ikegaya Y. Action-potential modulation during axonal conduction. Science. 2011;331:599-601.
61. Anderson CM, Swanson RA. Astrocyte glutamate transport: review of properties, regulation, and physiological functions. Glia. 2000;32:1-14.
62. Domercq M, Sánchez-Gómez MV, Areso P, Matute C. Expression of glutamate transporters in rat optic nerve oligodendrocytes. Eur J Neurosci. 1999;11:2226-2236.
63. Arranz AM, Hussein A, Alix JJ, Pérez-Cerdá F, Allcock N, Matute C, et al. Functional glutamate transport in rodent optic nerve axons and glia. Glia. 2008;56:1353-1367.
64. Domercq M, Etxebarria E, Pérez-Samartín A, Matute C. Excitotoxic oligodendrocyte death and axonal damage induced by glutamate transporter inhibition. Glia. 2005;52:36-46.
65. Domercq M, Sánchez-Gómez MV, Sherwin C, Etxebarria E, Fern R, Matute C. System xc-And glutamate transporter inhibition mediates microglial toxicity to oligodendrocytes. J Immunol. 2007;178:6549-6556.
66. Pampliega O, Domercq M, Soria FN, Villoslada P, Rodríguez- Antigüedad A, Matute C. Increased expression of cystine/glutamate antiporter in multiple sclerosis. J Neuroinflammation. 2011;8:63.
67. Matute C, Cavaliere F. Neuroglial interactions mediated by purinergic signalling in the pathophysiology of CNS disorders. Semin Cell Dev Biol. 2011;22:252-259.
68. Fields RD. Nonsynaptic and nonvesicular ATP release from neurons and relevance to neuron-glia signaling. Semin Cell Dev Biol. 2011;22:214-219.
69. James G, Butt AM. P2Y and P2X purinoceptor mediated Ca2+ signalling in glial cell pathology in the central nervous system. Eur J Pharmacol. 2002;447:247-260.
70. Matute C, Torre I, Pérez-Cerdá F, Pérez- Samartín A, Alberdi E, Etxebarria E, et al. P2X(7) receptor blockade prevents ATP excitotoxicity in oligodendrocytes and ameliorates experimental autoimmune encephalomyelitis. J Neurosci. 2007;27:9525-9533.
71. Butt AM. ATP: a ubiquitous gliotransmitter integrating neuron-glial networks. Semin Cell Dev Biol. 2011;22:205-213.
72. Burnstock G, Krügel U, Abbracchio MP, Illes P. Purinergic signalling: from normal behaviour to pathological brain function. Prog Neurobiol. 2011;95:229-274.
73. Ransom B, Goldberg M, Baltan S. Molecular pathophysiology of white matter anoxic/ischemic injury. In: Mohr JP, Wolf P, Grotta J, Mayberg M, Moskowitz M, Von Kummer R, eds. Stroke: Pathophysiology, diagnosis, and management. New York: Elsevier; 2011:122-137.
74. Stirling DP, Stys PK. Mechanisms of axonal injury: internodal nanocomplexes and calcium deregulation. Trends Mol Med. 2010;16:160-170.
75. Ouardouz M, Nikolaeva MA, Coderre E, Zamponi GW, McRory JE, Trapp BD, et al. Depolarization-induced Ca2+ release in ischemic spinal cord white matter involves L-Type Ca2+ channel activation of ryanodine receptors. Neuron. 2003;40:53-63.
76. Ruiz A, Matute C, Alberdi E. Intracellular Ca2+ release through ryanodine receptors contributes to AMPA receptor-mediated mitochondrial dysfunction and ER stress in oligodendrocytes. Cell Death Dis. 2010;1:e54.
77. Sánchez-Gómez MV, Alberdi E, Ibarretxe G, Torre I, Matute C. Caspasedependent and caspase-independent oligodendrocyte death mediated by AMPA and kainate receptors. J Neurosci. 2003;23:9519-9528.
78. Frenguelli BG, Wigmore G, Llaudet E, Dale N. Temporal and mechanistic dissociation of ATP and adenosine release during ischaemia in the mammalian hippocampus. J Neurochem. 2007;101:1400-1413.
79. Arbeloa J, Pérez-Samartín A, Gottlieb M, Matute C. P2X7 receptor blockade prevents ATP excitotoxicity in neurons and reduces brain damage after ischemia. Neurobiol Dis. 2012;45:954-961.
80. Aurell A, Rosengren LE, Karlsson B, Olsson JE, Zbornikova V, Haglid KG. Determination of S-100 and glial fibrillary acidic protein concentrations in cerebrospinal fluid after brain infarction. Stroke. 1991;22:1254-1258.
81. Murphy S. Production of nitric oxide by glial cells: regulation and potential roles in the CNS. Glia. 2000;29:1-13.